España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Algernon Pharmaceuticals
AGNPF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Algernon Pharmaceuticals (AGNPF) Forecast
News
Earnings
Algernon Pharmaceuticals (AGNPF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Algernon Pharmaceuticals (OTC:AGNPF) Stock
Algernon Pharmaceuticals Stock (OTC: AGNPF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Lara Goldstein
Wednesday, April 03, 2024
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Lara Goldstein
Monday, August 14, 2023
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Lara Goldstein
Tuesday, August 08, 2023
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
Vuk Zdinjak
Monday, June 05, 2023
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Lara Goldstein
Tuesday, April 04, 2023
How To Finance A Psychedelics Business? Learn From These Four Companies
Lara Goldstein
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
Lara Goldstein
Tuesday, March 07, 2023
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Lara Goldstein
Friday, March 03, 2023
Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
The Dales Report
Thursday, March 02, 2023
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
Lara Goldstein
Tuesday, February 28, 2023
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein
Tuesday, February 21, 2023
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
Lara Goldstein
Thursday, February 16, 2023
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Lara Goldstein
Wednesday, January 18, 2023
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Lara Goldstein
Tuesday, January 03, 2023
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Lara Goldstein
Thursday, December 15, 2022
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Lara Goldstein
Tuesday, November 22, 2022
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein
Wednesday, November 16, 2022
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Lara Goldstein
Monday, October 24, 2022
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Lara Goldstein
Monday, September 12, 2022
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Lara Goldstein
Thursday, September 08, 2022
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Lara Goldstein
Tuesday, August 23, 2022
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Lara Goldstein
Monday, July 18, 2022
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Vandana Singh
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
Monday, September 13, 2021
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman
Tuesday, August 03, 2021
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman
Monday, June 21, 2021
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman
Tuesday, April 06, 2021
Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Natan Ponieman
Saturday, February 06, 2021
Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization
Natan Ponieman
